Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

NIDA K LAURIN

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1306887963
CMS profile
103990
Location
SCOTTSDALE, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$141,504.58

232 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 5; records 51–100 of 232 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

NIDA K LAURIN

NPI 1306887963 · CMS profile ID 103990

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

SCOTTSDALE, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 5; records 51–100 of 232 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1306887963?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
NIDA K LAURIN, NPI 1306887963, CMS profile ID 103990. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 232 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1306887963?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). NIDA K LAURIN, NPI 1306887963, CMS profile ID 103990. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 232 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1306887963?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
NIDA K LAURIN, NPI 1306887963, CMS profile ID 103990, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 5; records 51–100 of 232 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1306887963?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

232 matching records · $141,504.58 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 232 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 232.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
EMD Serono, Inc. $125.0009/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032427637 CMS
Eisai Inc. $116.9009/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023325653 CMS
Novartis Pharmaceuticals Corporation $140.0009/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992174571 CMS
Horizon Therapeutics plc $46.2909/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 987035837 CMS
Biogen, Inc. $22.8309/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012249149 CMS
Biogen, Inc. $27.0009/08/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012266437 CMS
Biogen, Inc. $3,065.0009/08/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012272753 CMS
GENZYME CORPORATION $48.6009/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049970367 CMS
Biogen, Inc. $59.2909/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012123897 CMS
EMD Serono, Inc. $48.4209/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032395695 CMS
EMD Serono, Inc. $194.4008/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032552363 CMS
EMD Serono, Inc. $111.9408/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032552611 CMS
Biogen, Inc. $49.7308/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012128187 CMS
Biogen, Inc. $3,678.0008/14/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012132455 CMS
Biogen, Inc. $45.4508/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012148601 CMS
Biogen, Inc. $10.0008/14/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012178769 CMS
IDORSIA PHARMACEUTICALS US INC $12.2508/14/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034358805 CMS
IDORSIA PHARMACEUTICALS US INC $2,545.8308/14/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034358813 CMS
GENZYME CORPORATION $31.0608/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049970355 CMS
GENZYME CORPORATION $3,066.0008/11/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049970359 CMS
GENZYME CORPORATION $31.0508/11/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049970363 CMS
Biogen, Inc. $105.5608/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012177017 CMS
Horizon Therapeutics plc $2,750.0008/08/2023 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 987035831 CMS
Horizon Therapeutics plc $35.7008/08/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 987035833 CMS
Horizon Therapeutics plc $66.1308/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 987035835 CMS
GENZYME CORPORATION $36.0808/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049970341 CMS
GENZYME CORPORATION $6,132.0008/03/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049970345 CMS
GENZYME CORPORATION $266.4708/03/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049970349 CMS
GENZYME CORPORATION $608.4208/03/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049970353 CMS
GENZYME CORPORATION $79.4208/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049970371 CMS
GENZYME CORPORATION $2,628.0008/03/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049970375 CMS
GENZYME CORPORATION $169.4608/03/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049970379 CMS
GENZYME CORPORATION $599.4008/03/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049970385 CMS
GENZYME CORPORATION $22.0008/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049970487 CMS
GENZYME CORPORATION $418.6608/03/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049970491 CMS
GENZYME CORPORATION $28.8208/03/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049970495 CMS
GENZYME CORPORATION $60.0008/03/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049970499 CMS
TG Therapeutics, Inc. $101.9908/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051474071 CMS
Alexion Pharmaceuticals, Inc. $86.8507/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017002627 CMS
EMD Serono, Inc. $7,200.0007/25/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1052754633 CMS
E.R. Squibb & Sons, L.L.C. $88.8207/20/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015109965 CMS
Horizon Therapeutics plc $107.3307/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 987035829 CMS
E.R. Squibb & Sons, L.L.C. $4,320.0007/17/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015109943 CMS
EMD Serono, Inc. $74.6707/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032550931 CMS
TG Therapeutics, Inc. $119.2907/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051474091 CMS
IDORSIA PHARMACEUTICALS US INC $40.1407/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034590791 CMS
Novartis Pharmaceuticals Corporation $57.5107/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992174567 CMS
Horizon Therapeutics plc $167.6906/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 987035827 CMS
Celgene Corporation $59.4106/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015109954 CMS
EMD Serono, Inc. $3,273.0006/27/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032333609 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $201,822.18 356
PY2020 $94,635.78 168
PY2021 $97,372.61 150
PY2022 $152,691.14 239
PY2023 $141,504.58 232
PY2024 $121,351.63 192
PY2025 $159,539.72 228

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $879,811.40 40
PY2024 Recipient $2,485.09 16
PY2024 Principal investigator $341,227.44 31
PY2023 Principal investigator $61,630.92 22
PY2021 Principal investigator $33,904.10 25
PY2020 Principal investigator $20,180.00 11

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

40 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 GENZYME CORPORATION $4,757.45 12/08/2025 Non-covered Recipient Entity
Imaging Endpoints Ii Llc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226156340
Principal investigator 1 GENZYME CORPORATION $8,916.85 11/17/2025 Non-covered Recipient Entity
Imaging Endpoints Ii Llc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226156319
Principal investigator 1 GENZYME CORPORATION $28,796.60 11/17/2025 Non-covered Recipient Entity
Imaging Endpoints Ii Llc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226156322
Principal investigator 1 GENZYME CORPORATION $4,410.00 11/17/2025 Non-covered Recipient Entity
Imaging Endpoints Ii Llc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226156327
Principal investigator 1 Amgen Inc. $42,950.00 11/07/2025 Non-covered Recipient Entity
IMAGING ENDPOINTS II LLC
A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Pharmacodynamics, Clinical Effects, and Safety Between ABP 692 and Ocrevus (Ocrelizumab) in Subjects With Relapsing-remitting Multiple Sclerosis No dispute reported 06/30/2026 1246642583
Principal investigator 1 GENZYME CORPORATION $9,242.45 09/29/2025 Non-covered Recipient Entity
Imaging Endpoints Ii Llc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226156261
Principal investigator 1 GENZYME CORPORATION $7,234.85 09/29/2025 Non-covered Recipient Entity
Imaging Endpoints Ii Llc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226156265
Principal investigator 1 GENZYME CORPORATION $100.00 09/03/2025 Non-covered Recipient Entity
Imaging Endpoints Ii Llc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226156251
Principal investigator 1 GENZYME CORPORATION $4,560.00 08/11/2025 Non-covered Recipient Entity
Imaging Endpoints Ii Llc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226156228
Principal investigator 1 GENZYME CORPORATION $4,332.45 08/11/2025 Non-covered Recipient Entity
Imaging Endpoints Ii Llc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226156231
Principal investigator 1 GENZYME CORPORATION $12,730.55 08/04/2025 Non-covered Recipient Entity
Imaging Endpoints Ii Llc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226156205
Principal investigator 1 GENZYME CORPORATION $23,272.45 08/04/2025 Non-covered Recipient Entity
Imaging Endpoints Ii Llc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226156209
Principal investigator 1 GENZYME CORPORATION $1,751.30 08/04/2025 Non-covered Recipient Entity
Imaging Endpoints Ii Llc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226156217
Principal investigator 1 GENZYME CORPORATION $225.00 07/28/2025 Non-covered Recipient Entity
Imaging Endpoints Ii Llc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226156220
Principal investigator 1 GENZYME CORPORATION $12,019.00 07/28/2025 Non-covered Recipient Entity
Imaging Endpoints Ii Llc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226156225
Principal investigator 1 UCB SA $27,469.86 07/04/2025 Non-covered Recipient Entity
IMAGING ENDPOINTS II LLC
A MULTICENTER PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF UCB0022 IN STUDY PARTICIPANTS WITH ADVANCED Parkinsons DISEASE No dispute reported 06/30/2026 1246656618
Principal investigator 1 GENZYME CORPORATION $4,964.70 07/02/2025 Non-covered Recipient Entity
Imaging Endpoints Ii Llc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226156175
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $62,663.75 06/24/2025 Non-covered Recipient Entity
Imaging Endpoints, Llc
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Agitation Associated with Alzheimers Disease No dispute reported 06/30/2026 1235996705
Principal investigator 1 GENZYME CORPORATION $19,376.40 06/16/2025 Non-covered Recipient Entity
Imaging Endpoints Ii Llc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226156106
Principal investigator 1 GENZYME CORPORATION $5,106.40 05/19/2025 Non-covered Recipient Entity
Imaging Endpoints Ii Llc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226156124
Principal investigator 1 GENZYME CORPORATION $1,150.00 05/19/2025 Non-covered Recipient Entity
Imaging Endpoints Ii Llc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226156134
Principal investigator 1 GENZYME CORPORATION $4,612.35 04/21/2025 Non-covered Recipient Entity
Imaging Endpoints Ii Llc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226156076
Principal investigator 1 GENZYME CORPORATION $175.00 04/02/2025 Non-covered Recipient Entity
Imaging Endpoints Ii Llc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226156050
Principal investigator 1 Genentech, Inc. $10,000.00 03/25/2025 Non-covered Recipient Entity
IMAGING ENDPOINTS II LLC
Ocrevus Subcutaneous Study for Safety and Tolerability No dispute reported 06/30/2026 1211614366
Principal investigator 1 GENZYME CORPORATION $4,535.00 03/17/2025 Non-covered Recipient Entity
Imaging Endpoints Ii Llc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226155938
Principal investigator 1 GENZYME CORPORATION $2,553.20 03/17/2025 Non-covered Recipient Entity
Imaging Endpoints Ii Llc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226155945
Principal investigator 1 ABBVIE INC. $2,000.00 03/13/2025 Non-covered Recipient Entity
CLINICAL ENDPOINTS LLC
M21-307 - Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 1202462991
Principal investigator 1 GENZYME CORPORATION $12,054.40 02/24/2025 Non-covered Recipient Entity
Imaging Endpoints Ii Llc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226156008
Principal investigator 1 GENZYME CORPORATION $5,892.95 02/24/2025 Non-covered Recipient Entity
Imaging Endpoints Ii Llc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226156015
Principal investigator 1 GENZYME CORPORATION $50.00 02/10/2025 Non-covered Recipient Entity
Imaging Endpoints Ii Llc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226155920
Principal investigator 1 GENZYME CORPORATION $4,585.00 02/10/2025 Non-covered Recipient Entity
Imaging Endpoints Ii Llc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226155933
Principal investigator 1 GENZYME CORPORATION $4,685.00 02/10/2025 Non-covered Recipient Entity
Imaging Endpoints Ii Llc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226155952
Principal investigator 1 GENZYME CORPORATION $2,896.10 02/10/2025 Non-covered Recipient Entity
Imaging Endpoints Ii Llc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226155986
Principal investigator 1 Sage Therapeutics, LLC $11,660.66 02/06/2025 Non-covered Recipient Entity
IMAGING ENDPOINTS II LLC
A Study to Evaluate the Long-term Safety and Tolerability of SAGE-324 in Participants With Essential Tremor No dispute reported 06/30/2026 1206580337
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $5,360.09 01/27/2025 Non-covered Recipient Entity
Imaging Endpoints, Llc
A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (TargetTau-1) No dispute reported 06/30/2026 1235996707
Principal investigator 1 ABBVIE INC. $675.00 01/20/2025 Non-covered Recipient Entity
CLINICAL ENDPOINTS LLC
M21-307 - Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 1202440071
Principal investigator 1 ABBVIE INC. $19.20 01/14/2025 Non-covered Recipient Entity
CLINICAL ENDPOINTS LLC
M21-307 - Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 1202438338
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $416,056.05 01/13/2025 Non-covered Recipient Entity
Imaging Endpoints, Llc
A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (TargetTau-1) No dispute reported 06/30/2026 1235996703
Principal investigator 1 GENZYME CORPORATION $10,812.75 01/13/2025 Non-covered Recipient Entity
Imaging Endpoints Ii Llc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226156055
Principal investigator 1 UCB SA $95,158.59 01/07/2025 Non-covered Recipient Entity
IMAGING ENDPOINTS II LLC
A MULTICENTER PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF UCB0022 IN STUDY PARTICIPANTS WITH ADVANCED Parkinsons DISEASE No dispute reported 06/30/2026 1246658468